Evidence map›Paper›PMID 38544844›Full record

ReviewFrontiers in psychiatry2024

A link between ghrelin and major depressive disorder: a mini review.

Michał Lis, Tymoteusz Miłuch, Maciej Majdowski, Tomasz Zawodny

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Michał LisDepartment of Internal Medicine, Endocrinology and Diabetology, Czerniakowski Hospital, Warsaw, Poland.
Tymoteusz MiłuchDepartment of Internal Medicine, Endocrinology and Diabetology, Czerniakowski Hospital, Warsaw, Poland.
Maciej MajdowskiDepartment of Internal Medicine, Endocrinology and Diabetology, Czerniakowski Hospital, Warsaw, Poland.
Tomasz ZawodnyDepartment of Internal Medicine, Endocrinology and Diabetology, Czerniakowski Hospital, Warsaw, Poland.
Cardinal Stefan Wyszyński University in Warsaw · PLUczelnia Łazarskiego · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ghrelin is primarily responsible for regulating energy balance, as it increases appetite. However, in recent years, its new physiological functions have been discovered-it regulates lipogenesis, plays a role in the development of insulin resistance, and even acts protectively on heart muscle. Moreover, ghrelin was associated with many psychiatric disorders, including major depressive disorder (MDD) or schizophrenia. Ghrelin levels were elevated in patients diagnosed with depression and in patients after suicide attempts. Moreover, ghrelin was connected to depression among postmenopausal women and was shown to be a predictive marker of MDD among the elderly. Ghrelin may influence mood disorders in various ways: by regulating stress response or inflammation or altering neurotransmission in the amygdala, dorsal raphe nucleus, or hippocampus, brain regions previously connected to the pathophysiology of MDD. Genetic variants of ghrelin and its receptor have also been associated with depression. Moreover, ghrelin can interfere with the antidepressant's action and may play a role in treatment resistance. This review highlights ghrelin's role in depression, summarizes the existing knowledge on the subject, and presents ideas for further research.

Indexed as

depressionghrelinmajor depressive disorder (MDD)metabolic hormonemood disorder

Identifiers

PMID38544844
PMCPMC10965711
OpenAlexW4392756236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.